Akari Therapeutics Plc Sponsored ADR Stock News

Watch the “What This Means” video here

New cash portion of offering includes >20% participation from Directors, Officers and Executive Management New cash portion of offering includes >20% participation from Directors, Officers and Executive Management

Data highlights the ability of Akari's Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models, potentially addressing one of the most lethal cancers with the lowest survival rates

Access the Akari CEO Corner  here TAMPA, Fla. and LONDON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced the publication of a new CEO Corner segment, now available on the Company's website.

Access the Akari CEO Corner  here BOSTON and LONDON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced the next CEO Corner segment has been published on the Company's website. For this CEO Corner segment, Abizer Gaslightwala, CEO of Akari, provides an overview...

Akari Therapeutics, Plc ( AKTX ) Shareholder/Analyst Call November 18, 2025 11:00 AM EST Company Participants Abizer Gaslightwala - CEO, President & Director Satyajit Mitra - Executive Director & Head of Oncology Conference Call Participants Jenene Thomas Presentation Jenene Thomas Okay. We are ready to get started, and welcome, everyone, to the Akari Therapeutics Corporate Update Webcast.

More than 20 years of financial and operational leadership in biopharma, including $170M+ in capital raised, global commercialization experience, and a proven track record scaling companies from preclinical to clinical milestones More than 20 years of financial and operational leadership in biopharma, including $170M+ in capital raised, global commercialization experience, and a proven track re...

Data presented at the 40 th Annual Society for Immunotherapy of Cancer (SITC) Meeting The spliceosome targeting payload, PH1, demonstrates the ability to induce both cancer cell cytotoxicity and activation of anti-tumor immunity through multiple mechanisms Treatment with a Trastuzumab-PH1 ADC monotherapy drove macrophages to polarize into an anti-tumor/inflammatory state and caused expansion of...